U.S. FDA scientists said that there is a risk that Novo Nordisk's (NVO) once-weekly insulin icodec, under investigation for type 1 and type 2 diabetes, can lead to extremely low blood sugar levels. In...
Source LinkU.S. FDA scientists said that there is a risk that Novo Nordisk's (NVO) once-weekly insulin icodec, under investigation for type 1 and type 2 diabetes, can lead to extremely low blood sugar levels. In...
Source Link
Comments